DPP

Franklin Whole Home Receives Permitting Green Light from Honolulu

Retrieved on: 
Tuesday, January 10, 2023
M&M, ESS, Coal, Booth, City, LFP, FHP, AC, County, SAN, Intersolar, DPP, Western literature, Safety, Certification, Material, Renewable energy

SAN FRANCISCO, Jan. 10, 2023 /PRNewswire/ -- FranklinWH, a leading whole-home energy management solution provider, announced today that it has received the coveted Materials and Methods (M&M) Certification from the City and County of Honolulu's Department of Planning and Permitting (DPP). With the announcement, solar energy storage system (ESS) installers on the island of Oahu can now reference the Franklin Home Power M&M Certification to fast-track the standard residential permitting process and save time and money on a homeowner's rooftop solar and storage project. Now, homeowners can start to enjoy the benefits of their solar and FranklinWH system sooner without uncontrollable permitting delays.

Key Points: 
  • Now, homeowners can start to enjoy the benefits of their solar and FranklinWH system sooner without uncontrollable permitting delays.
  • Franklin Home Power (FHP) is a whole-home energy management solution that integrates solar, battery, grid, and generator power sources and manages them to optimize the safety, reliability, and efficiency of a home's energy needs.
  • With the M&M Certification, installers can now also offer the system to residents of Honolulu, the state's most populous county.
  • For more information about FranklinWH's energy management solutions, visit FranklinWH during the Intersolar conference February 14 -16, 2023 in Long Beach, CA at Booth #723.

Sharecare's new mindfulness-driven Diabetes Prevention Program recognized and approved by CDC

Retrieved on: 
Monday, January 9, 2023
Research, CDC, Overweight, Shame, Digital, Metabolism, Disease, Eating, Curriculum, DPP, Exercise, Health, National Diabetes Education Program, Therapy, Minnesota Eating Behavior Survey, MPH, Pharmaceutical industry, Toy, MD

ATLANTA, Jan. 9, 2023 /PRNewswire/ -- Sharecare (Nasdaq: SHCR), the digital health company that helps people manage all their health in one place, today announced that its new mindfulness-driven Diabetes Prevention Program (DPP) has been recognized and approved by the CDC. Available exclusively to Sharecare's employer, health plan, and government customers through its digital therapeutics marketplace, the CDC-approved program launched to eligible client populations on Jan. 1, 2023.

Key Points: 
  • New digital therapeutic from Sharecare is first evidence-based, mindfulness-driven diabetes prevention curriculum recognized and approved by CDC
    ATLANTA, Jan. 9, 2023 /PRNewswire/ -- Sharecare (Nasdaq: SHCR), the digital health company that helps people manage all their health in one place, today announced that its new mindfulness-driven Diabetes Prevention Program (DPP) has been recognized and approved by the CDC.
  • Available exclusively to Sharecare's employer, health plan, and government customers through its digital therapeutics marketplace, the CDC-approved program launched to eligible client populations on Jan. 1, 2023.
  • Developed from over 10 years of research by neuroscientist, addiction psychiatrist, and Sharecare's chief medical officer, Jud Brewer, MD, MPH, Eat Right Now is scientifically proven to reduce craving-related eating by 40%.
  • "While other diabetes prevention programs do a fine job training participants on the basics of nutrition, exercise, and metabolism, they primarily rely on willpower to drive actual behavior change, which doesn't always work in the long term," said Dr.

Pertamina International Shipping (PIS) Secures Collaboration Agreements with Global Partners

Retrieved on: 
Saturday, January 7, 2023
PIS, Commercial, MOC, Ammonia, BGN, CPP, Acquisition, LPG, DPP, Maintenance, VLGC, Joint venture, Liquefied petroleum gas, Private investigator, Airline, HOA, Pertamina

JAKARTA, Jan 7, 2023 - (ACN Newswire) - PT Pertamina International Shipping (PIS) has secured two collaboration agreements with global partners.

Key Points: 
  • JAKARTA, Jan 7, 2023 - (ACN Newswire) - PT Pertamina International Shipping (PIS) has secured two collaboration agreements with global partners.
  • PIS signs MoC with Elite Tankship, signed by the CEO of Elite Tankship, Mangish Kakodkar, and the Director of Operations of PIS, Brilian Perdana.
  • Witnessed by CEO PIS, Yoki Firnandi, President Director Pertamina, Nicke Widyawati, President Commissioner Pertamina, Basuki Tjahaja Purnama, and H.E Ambassador of Indonesia for UAE, Husin Bagis.
  • Elite Tankship, headquartered in Singapore, established collaboration with PIS in chartering the VLCC Pertamina Prime, the largest owned vessel and the company's pride, in May 2022 for a six-year contract period.

Digital Diabetes Management Market Size to Reach USD 37.8 Billion in 2030 | Emergen Research

Retrieved on: 
Wednesday, December 21, 2022
Digital technology, Data visualization, USD, World Health Organization, CGMS-A, Patient, Cyberattack, WHO, Diabetes, Obesity, Health, Dexcom, Roche, Digital, Eli Lilly and Company, Medtronic, Partnership, Growth, Zur Rose Group, Risk, DPP, Country, National Association Medical Staff Services, Prescription, Prevalence, Eating, Bayer, DM, Incidence, LifeScan, ICT, Medical device, Pharmaceutical industry

VANCOUVER, B.C., Dec. 21, 2022 /PRNewswire/ -- The digital diabetes management market size reached USD 13.6 Billion in 2021 and is expected to register a CAGR of 12.0% during the forecast period, according to latest analysis by Emergen Research .

Key Points: 
  • VANCOUVER, B.C., Dec. 21, 2022 /PRNewswire/ -- The digital diabetes management market size reached USD 13.6 Billion in 2021 and is expected to register a CAGR of 12.0% during the forecast period, according to latest analysis by Emergen Research .
  • As a result, the management and treatment of many diseases are depending on the widespread use of information and communication technology (ICT)-based digital health systems, which is driving the adoption of digital diabetes management services in the market.
  • Demand for digital diabetes management devices has significantly increased over the years due to the increasing prevalence of diabetes and obesity around the world.
  • The digital diabetes management market is expected to register a CAGR of 12.0% over the forecast period and revenue is projected to increase from USD 13.6 Billion in 2021 to USD 37.8 Billion in 2030.

Digital Diabetes Management Market Size to Reach USD 37.8 Billion in 2030 | Emergen Research

Retrieved on: 
Wednesday, December 21, 2022
Digital technology, Data visualization, USD, World Health Organization, CGMS-A, Patient, Cyberattack, WHO, Diabetes, Obesity, Health, Dexcom, Roche, Digital, Eli Lilly and Company, Medtronic, Partnership, Growth, Zur Rose Group, Risk, DPP, Country, National Association Medical Staff Services, Prescription, Prevalence, Eating, Bayer, DM, Incidence, LifeScan, ICT, Medical device, Pharmaceutical industry

VANCOUVER, B.C., Dec. 21, 2022 /PRNewswire/ -- The digital diabetes management market size reached USD 13.6 Billion in 2021 and is expected to register a CAGR of 12.0% during the forecast period, according to latest analysis by Emergen Research .

Key Points: 
  • VANCOUVER, B.C., Dec. 21, 2022 /PRNewswire/ -- The digital diabetes management market size reached USD 13.6 Billion in 2021 and is expected to register a CAGR of 12.0% during the forecast period, according to latest analysis by Emergen Research .
  • As a result, the management and treatment of many diseases are depending on the widespread use of information and communication technology (ICT)-based digital health systems, which is driving the adoption of digital diabetes management services in the market.
  • Demand for digital diabetes management devices has significantly increased over the years due to the increasing prevalence of diabetes and obesity around the world.
  • The digital diabetes management market is expected to register a CAGR of 12.0% over the forecast period and revenue is projected to increase from USD 13.6 Billion in 2021 to USD 37.8 Billion in 2030.

Prime Factors Recognized in 2022 Gartner® Hype Cycle™ for Privacy

Retrieved on: 
Wednesday, December 21, 2022
Organization, Architecture, Rest, Risk, FPE, DPP, Publication, Research, Digital, Prime Factors (Star Trek: Voyager), Hype cycle, Online shopping, Software, Cryptocurrency, Gartner, Privacy

EUGENE, Ore., Dec. 20, 2022 /PRNewswire-PRWeb/ -- Prime Factors, a leader in application-level data protection, has been recognized by Gartner® among Sample Vendors in the Hype Cycle for Privacy, 2022.

Key Points: 
  • Prime Factors, a leader in application-level data protection, has been recognized by Gartner® among Sample Vendors in the Hype Cycle for Privacy, 2022.
  • EUGENE, Ore., Dec. 20, 2022 /PRNewswire-PRWeb/ -- Prime Factors , a leader in application-level data protection, has been recognized by Gartner ® among Sample Vendors in the Hype Cycle for Privacy, 2022.
  • In the Hype Cycle for Privacy, 2022, Gartner recognized Prime Factors among Sample Vendors in Format-preserving encryption, a category of privacy, defined by the research firm which "protects data at rest and in use, and when accessed through applications."
  • "It's clear to us that modern data protection and data privacy requires being able to deliver a broad spectrum of data protection functionality," said Henry Cheli, president of Prime Factors.

Institute for Portfolio Alternatives Elects New Board Members for 2023

Retrieved on: 
Friday, December 16, 2022
PDI, KKR, Chirag, IPA, CNL, Ameriprise Financial, Alternative investment, CNL Financial Group, Human, General counsel, Financial compensation, Wealth, BDC, Blackstone, Product strategy, Secretariat of Public Security, Senior, CIM Group, Capital market, Cetera Financial Group, NAV, DPP, Moody's Investors Service, Management, Financial adviser, Real estate

WASHINGTON, Dec. 16, 2022 /PRNewswire/ -- The Institute for Portfolio Alternatives (IPA) today announced it has elected 11 new directors. The IPA Board of Directors consists of senior executive leaders from all corners of the portfolio diversifying investments industry, each elected to a three-year term effective January 1, 2023. 

Key Points: 
  • WASHINGTON, Dec. 16, 2022 /PRNewswire/ -- The Institute for Portfolio Alternatives (IPA) today announced it has elected 11 new directors.
  • The IPA Board of Directors consists of senior executive leaders from all corners of the portfolio diversifying investments industry, each elected to a three-year term effective January 1, 2023.
  • In addition to naming 11 new directors, the Board of Directors also elected CNL Financial Group's Chirag Bhavsar,as chair-elect for 2023.
  • "The IPA Board brings together a group of leaders who represent our guiding principles as well as the diversity of our community.

Yes Health Teams with Santa Clara Family Health Plan to Bring Diabetes Prevention Program to At-Risk Medi-Cal Members

Retrieved on: 
Monday, December 12, 2022
Medi-Cal, Health, Physician, Partnership, Patient, Meal, Nutritionist, Prediabetes, Diabetes, Obesity, Weight loss, Face, Artificial intelligence, DPP, Health equity, SAN, CDC, Pharmaceutical industry, Medical device, Risk management

SAN FRANCISCO, Dec. 12, 2022 /PRNewswire-PRWeb/ -- Yes Health, a leading digital health provider focused on weight loss, diabetes prevention and concierge health coaching, today announced it is teaming with Santa Clara Family Health Plan (SCFHP) to provide its all-mobile Diabetes Prevention Program (DPP) to at-risk Medi-Cal members at no cost. The innovative collaboration will give eligible members access to Yes Health's award-winning, easy-to-use service that has deep experience producing positive health outcomes and lowering costs for many populations, but especially Medi-Cal members.

Key Points: 
  • SAN FRANCISCO, Dec. 12, 2022 /PRNewswire-PRWeb/ -- Yes Health , a leading digital health provider focused on weight loss, diabetes prevention and concierge health coaching, today announced it is teaming with Santa Clara Family Health Plan (SCFHP) to provide its all-mobile Diabetes Prevention Program (DPP) to at-risk Medi-Cal members at no cost.
  • "Yes Health's fully mobile program provides the convenience of a virtual diabetes prevention program our most at-risk members can use to lose weight and feel healthy."
  • Yes Health is a CDC-recognized lifestyle and behavioral-change system that combines technology tools and concierge health coaching in one digital health platform that's proven to prevent and manage chronic conditions.
  • Santa Clara Family Health Plan (SCFHP) is a local, community-based health plan dedicated to creating opportunities for better health and wellness for all.

The Worldwide Peptide Therapeutics Industry is Expected to Reach $58.4 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 1, 2022
Health, Biotechnology, Population growth, Innovation, Lysine, Colon, Peptide, Administration, Liraglutide, CVD, Prevalence, Serum, Blood, Disorder, Hormone, Brain, Instability, Neuropeptide, Route of administration, Ageing, Protein, Pancreas, Inflammation, Medicine, Death, Disease, Half-life, Carbon, Hypercholesterolemia, DPP, Lung cancer, Growth hormone, Cardiovascular disease, Cancer, Absorption, Risk, Therapy, Lanreotide, Hyperglycemia, Water, Application, Organic acid, Breast cancer, Somatostatin, Plasma, Breast, Obesity, Fine chemical, Vaccine

The Global Peptide Therapeutics Market size is expected to reach $58.4 billion by 2028, rising at a market growth of 6.3% CAGR during the forecast period.

Key Points: 
  • The Global Peptide Therapeutics Market size is expected to reach $58.4 billion by 2028, rising at a market growth of 6.3% CAGR during the forecast period.
  • Peptide therapeutics are polypeptides or peptides (oligomers or short polymers of amino acids) that are utilized to treat disorders.
  • Peptide treatments replicate natural peptide functions such as hormones, neurotransmitters, growth factors, ion channel ligands, and anti-infectives.
  • Liraglutide, the most popular diabetic medicine on the market, contains a lipid chain that increases plasma circulation and provides long-term absorption.

Chembio Announces FDA CLIA Waiver Submission for DPP HIV-Syphilis System

Retrieved on: 
Monday, November 28, 2022
COVID-19, Infection, Vertically transmitted infection, Government, Diagnosis, CDC, Antibody, Food, Blood, Risk, Hospital, EUA, Bacteria, Infant, ANVISA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pregnancy, Patient, System, Annual report, Birth defect, PMA, CLIA, Disease, World Health Organization, DPP, Treponema pallidum, Clinical Laboratory, Coinfection, Sale, Fetus, Stillbirth, CE marking, Congenital syphilis, Woman, HIV, Syphilis, Plasma, FDA, Pharmaceutical industry, Treponema

We are pleased to communicate that our DPP HIV-Syphilis System has been submitted to FDA for CLIA waiver.

Key Points: 
  • We are pleased to communicate that our DPP HIV-Syphilis System has been submitted to FDA for CLIA waiver.
  • Upon receipt of CLIA waiver, we believe this will represent a large step forward in rapid testing for sexually transmitted infections.
  • We appreciate the collaboration with the FDA on this submission and look forward to continued dialog regarding our CLIA waiver application, said RichardL.
  • Chembios portfolio of DPP-based point-of-care tests with FDA regulatory approvals include the DPP HIV-Syphilis System (PMA approved), DPP HIV 1/2 Assay (PMA approved and CLIA waived), DPP Zika IgM System (510(k)), and DPP Ebola Antigen System (EUA).